Longeveron Inc (LGVN) Stock Analysis
Verdict: AVOID
Longeveron is a binary clinical-stage bet facing a critical August 2026 readout and an imminent cash crunch requiring immediate dilution.
Investment score: 38/100
Analysis as of
Is Longeveron Inc stock worth reviewing? AI model thesis
Longeveron is a micro-cap biotech with a high-stakes clinical catalyst (HLHS Phase 2b) in August 2026, but its deteriorating balance sheet makes an investment before the next financing round fundamentally reckless.
7-factor investment score
- Valuation: 35/100 (weight 20%)
- Financial Health: 15/100 (weight 15%)
- Technical Momentum: 30/100 (weight 15%)
- Earnings Quality: 40/100 (weight 15%)
- Insider Sentiment: 60/100 (weight 10%)
- Analyst Consensus: 75/100 (weight 10%)
- Risk-Adjusted Return: 35/100 (weight 15%)
Longeveron Inc opportunities and risks
What speaks for LGVN
- HLHS Phase 2b Readout (August 2026)
What speaks against LGVN
- Imminent Cash Exhaustion
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| LGVN | n/a | 12.1x | 0.0x | 65.1% | -1844.5% | -126.3% |
| OSRH | n/a | 5.0x | n/a | -70.0% | -525.1% | -41.6% |
| ACUT | n/a | 0.0x | 0.0x | 0.0% | 0.0% | — |
| PASG | n/a | 0.0x | 0.3x | 0.0% | 0.0% | -186.6% |
| QNCX | n/a | 0.0x | 0.2x | 0.0% | 0.0% | -715.9% |
| GRTX | 0.1x | 0.0x | n/a | 0.0% | 0.0% | -29.5% |
| Peer median | n/a | 0.0x | 0.0x | 0.0% | 0.0% | -114.1% |
Frequently asked questions about Longeveron Inc (LGVN)
Is LGVN stock a good investment?
The cached TradeMates AI model rates Longeveron Inc as AVOID with an investment score of 38/100. Longeveron is a micro-cap biotech with a high-stakes clinical catalyst (HLHS Phase 2b) in August 2026, but its deteriorating balance sheet makes an investment before the next financing round fundamentally reckless. This is algorithmic model output, not personal investment advice.
Is LGVN stock a buy?
The TradeMates model verdict for LGVN is AVOID with an investment score of 38/100. Treat this as a model signal to review, not a personal buy recommendation.